Alstonine (Anhydronium Indole Alkaloid · Antipsychotic Research)

Compound	Alstonine
Chemical class	Alkaloid — Indole (anhydronium heteroyohimbine; oxidised tetrahydroalstonine)
CAS	642-18-2
Primary source	Alstonia boonei; also Catharanthus roseus, Picralima nitida, Rauwolfia spp.
Key applications	Antipsychotic-like preclinical profile; anticancer research
Claim strength	Emerging
Typical form	Alstonia extract standardised to total indole alkaloids (availability on request)
Buy from Herbuno	Availability on request — request bulk pricing →

Name origin: Alstonine is named for the genus Alstonia, and structurally it is an anhydronium heteroyohimbine alkaloid — a fully aromatic, positively charged indole alkaloid, standing in the same oxidised relationship to tetrahydroalstonine that serpentine holds to ajmalicine. The three occupy the same biosynthetic branch of the monoterpenoid indole alkaloids. Traditional use: Alstonine occurs across a striking range of medicinal plants — Alstonia boonei, Catharanthus roseus, Picralima nitida, Rauwolfia caffra, and Rauwolfia vomitoria Elisabetsky 2006 — several of which have independent traditional uses in West African medicine. Most notably, alstonine is a constituent of plant preparations used by Nigerian traditional psychiatrists in the management of mental illness, and it is that ethnopsychiatric use that has driven much of its scientific interest. Research trajectory: Biomedical examination has established alstonine as bioactive and distinctive, with an antipsychotic-like behavioural profile that has been described as remarkably coherent with its traditional psychiatric use, alongside reported anticancer properties Elisabetsky 2006. Its pharmacology is atypical: it does not straightforwardly reproduce the receptor profile of conventional antipsychotic drugs, which is precisely what makes it interesting as a possible lead for mechanistically novel agents. Reviews of Alstonia boonei confirm alstonine among the alkaloids underlying the genus's broad pharmacology Adotey 2012. Commercial source: Alstonia extract standardised to total indole alkaloids is available from Herbuno on request.

---

Evidence for Alstonine Applications

Antipsychotic-like profile: Biomedical evaluation reveals alstonine to be bioactive and distinct in its antipsychotic properties, and its behavioural pharmacology has been characterised as remarkably coherent with its use by Nigerian traditional psychiatrists — an unusually direct convergence between an ethnomedical indication and a preclinical pharmacological profile Elisabetsky 2006. Claim strength: Emerging.

Mechanistic atypicality: Alstonine's profile does not simply reproduce that of conventional antipsychotics, and this mechanistic distinctiveness is the basis of interest in it as a potential lead for novel agents rather than as a botanical substitute for existing drugs Elisabetsky 2006. Claim strength: Emerging.

Anticancer research: Alongside its neuropharmacology, alstonine has been reported to possess anticancer properties in preclinical study, and reviews of the alkaloid document this second strand of activity Elisabetsky 2006. These findings remain at the laboratory stage. Claim strength: Emerging.

Broad botanical distribution: Alstonine occurs across Alstonia boonei, Catharanthus roseus, Picralima nitida, and Rauwolfia species Elisabetsky 2006, several of which are documented separately in HerbIQ; this cross-genus distribution reflects the shared strictosidine-derived biosynthesis of the Apocynaceae and means alstonine may be encountered in material sourced for quite different purposes. Claim strength: Emerging.

Whole-plant matrix: In Alstonia boonei, alstonine occurs alongside echitamine, echitamidine, and a range of triterpenoids and iridoids, so bark material delivers it within a complex mixture rather than as an isolated constituent Adotey 2012. Claim strength: Emerging.

---

Dosage & Formulator Specification

Alstonine is at an early, preclinical stage of evidence, and no established human dose exists. Its antipsychotic-like activity has been characterised in animal behavioural models, and those experimental exposures have no translation to supplement dosing; they are cited here for scientific context only.

An important boundary applies to how this compound may be discussed. Alstonine's most striking preclinical finding concerns antipsychotic-like activity, a domain squarely within serious mental illness and prescription pharmacotherapy. No botanical ingredient should be positioned in relation to psychiatric conditions, and this monograph documents the pharmacology as a matter of scientific record without implying any application to mental health. Formulators must not construct claims in that territory.

For material specification, the practical input is Alstonia extract standardised to total indole alkaloids by HPLC. Because alstonine also occurs in Catharanthus, Picralima, and Rauwolfia, the source species must be specified rather than assumed, and it is worth noting that some of those alternative sources carry their own potent and regulated alkaloids — Catharanthus the cytotoxic vinca precursors, Rauvolfia the antihypertensive esters — so alstonine content alone is a poor guide to a material's overall pharmacological character. Alstonia extract standardised to total alkaloids is available from Herbuno on request.

The convergence between alstonine's traditional and preclinical profiles deserves a note of scientific caution as well as interest. It is genuinely unusual for a compound's behavioural pharmacology in animal models to align so closely with the specific ethnomedical indication of the plants containing it, and that coherence is what has sustained research attention. But convergence is not proof: animal behavioural models of antipsychotic activity are imperfect proxies, and no controlled human evidence establishes efficacy or safety. The honest position is that alstonine is a scientifically interesting lead with a striking ethnopharmacological pedigree and an undeveloped clinical evidence base.

This monograph documents alstonine as a formulator reference within the HerbIQ index, connecting it to echitamine and tetrahydroalstonine alongside it and to serpentine in the wider heteroyohimbine group, and positions it honestly as an early-evidence compound available on request rather than a validated product.

---

Frequently Asked Questions — Alstonine

What is alstonine?
Alstonine is an anhydronium indole alkaloid found in Alstonia boonei, Catharanthus roseus, Picralima nitida, and Rauwolfia species. It is distinctive for an antipsychotic-like pharmacological profile that differs mechanistically from conventional antipsychotic drugs.

What is alstonine studied for?
Preclinical research characterises alstonine as having an atypical antipsychotic-like profile, and its behavioural pharmacology is notably coherent with its use by Nigerian traditional psychiatrists in plant-based preparations for mental illness. It has also been examined for anticancer activity. The evidence is preclinical.

Can I source alstonine from Herbuno?
Alstonia extract standardised to total indole alkaloids is available on request. Herbuno does not currently stock an alstonine-standardised product, so specification, availability, and bulk pricing would be arranged on enquiry.

How does alstonine relate to serpentine and tetrahydroalstonine?
All three are heteroyohimbine-type alkaloids of the same biosynthetic branch. Alstonine and serpentine are both fully aromatic anhydronium alkaloids, while tetrahydroalstonine is the reduced counterpart of alstonine, and the three co-occur across Apocynaceae genera including Alstonia, Catharanthus, and Rauwolfia.

Related compounds: Echitamine, Tetrahydroalstonine, Serpentine, Reserpine

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery